TMS CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 245 JPY | -2.78% |
|
-4.30% | +30.32% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 700M 4.49M | Sales 2025 * | - | Capitalization | 9.87B 63.37M |
|---|---|---|---|---|---|
| Net income 2024 * | -80M -513K | Net income 2025 * | -1.28B -8.18M | EV / Sales 2024 * | 14.1 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-112
x | P/E ratio 2025 * |
-7.66
x | Employees | 14 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.27% |
More Fundamentals
* Assessed data
More news
More recommendations
More news
| 1 day | -2.78% | ||
| 1 week | -4.30% | ||
| Current month | -0.41% | ||
| 1 month | -3.54% | ||
| 3 months | -16.95% | ||
| 6 months | -1.61% | ||
| Current year | +30.32% |
1 week
245.00
261.00
1 month
223.00265.00
Current year
171.00367.00
1 year
159.00460.00
3 years
159.001 188.00
5 years
159.001 188.00
10 years
159.001 188.00
| Managers | Title | Age | Since |
|---|---|---|---|
Keiji Hasumi
FOU | Founder | 66 | 05-02-16 |
| President | 57 | 11-04-30 | |
Go Ito
ADM | Chief Administrative Officer | 54 | 18-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| President | 57 | 11-04-30 | |
Reiko Namikawa
BRD | Director/Board Member | 70 | 21-04-30 |
Ken Takanashi
BRD | Director/Board Member | 60 | 20-02-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 245 | -2.78% | 170,500 |
| 24-05-09 | 252 | -2.70% | 199,100 |
| 24-05-08 | 259 | +1.97% | 379,300 |
| 24-05-07 | 254 | -0.78% | 197,300 |
| 24-05-02 | 256 | -1.16% | 260,100 |
Delayed Quote Japan Exchange, May 10, 2024 at 02:00 am EDT
More quotes
TMS Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and marketing of pharmaceuticals. The Company conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.
Calendar
2024-07-11
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
245
JPY
Average target price
760
JPY
Spread / Average Target
+210.20%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +30.32% | 63.35M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- 4891 Stock
